Specialist Technology Companies Under Chapter 18C: Minimum Market Cap and R&D Requirements

The Hong Kong Exchange’s Chapter 18C, introduced on 31 March 2023, was designed to capture a specific category of high-growth, pre-profit issuers that the Main Board’s traditional profit-based tests could not accommodate. As of Q2 2025, the pipeline has narrowed significantly: only five companies have successfully listed under this regime, with a combined market capitalisation at listing of approximately HKD 45 billion. The primary friction point is not the revenue threshold but the interaction between the minimum market capitalisation requirement and the qualifying research and development (R&D) expenditure calculation. For CFOs and sponsors evaluating this pathway, the precise arithmetic of the R&D “qualifying period” and the “significant investment” definition under Rule 18C.03(2) determines feasibility, not the headline market cap figures.

The Minimum Market Capitalisation Threshold: A Two-Tier Barrier

The HKD 8 Billion and HKD 15 Billion Distinctions

Chapter 18C establishes two distinct market capitalisation tiers, each tied to a company’s revenue profile. Under Rule 18C.03(2)(a), a Specialist Technology Company (“STC”) with annual revenue of at least HKD 250 million (the “Commercialisation Revenue Threshold”) must demonstrate a minimum market capitalisation at listing of HKD 8 billion. For an STC that has not yet crossed this revenue line—a pre-commercialisation company—the bar rises to HKD 15 billion under Rule 18C.03(2)(b). The HKEX’s Listing Decision LD143-2023 clarified that this revenue test is assessed on the basis of the most recent audited annual financial statements, not a trailing twelve-month or forecast figure. This distinction has practical consequences: a life sciences company with early-stage product sales of HKD 260 million but negative net profit qualifies for the HKD 8 billion threshold, whereas a deep-tech hardware company with zero revenue and a market valuation of HKD 14.5 billion cannot list under Chapter 18C at all.

Market Capitalisation Verification Mechanics

The HKEX requires that the minimum market cap be calculated based on the issue price in the prospectus and the total number of shares in issue immediately upon listing, including any shares to be issued pursuant to the over-allotment option (Rule 18C.04). This is not a theoretical valuation; it must be supported by a valuation report from a recognised independent valuer, as stipulated in the HKEX’s Guidance Letter HKEX-GL117-23. The valuer must apply a discounted cash flow or comparable company analysis, and the HKEX reserves the right to query the underlying assumptions, particularly the discount rate and terminal growth rate, for STCs in sectors with limited public comparables. In practice, the HKEX has rejected two applications where the valuation relied on a single comparable transaction from a jurisdiction with materially different regulatory risk profiles, such as a US-listed SPAC merger target.

The Research and Development Expenditure Calculation

Defining “Qualifying R&D Expenditure”

The R&D requirement under Rule 18C.03(2)(c) mandates that an STC must have incurred “significant investment” in R&D over at least two financial years prior to listing. The HKEX’s guidance in HKEX-GL117-23 defines this as R&D expenditure constituting at least 15% of total operating expenditure in each of those two years. Operating expenditure for this purpose excludes cost of goods sold, depreciation, and amortisation, a point that has caused confusion among applicants. For a hardware STC with HKD 100 million in cost of goods sold and HKD 50 million in R&D spend, the qualifying ratio is 50/150 = 33.3%, not 50/250 = 20%. The two-year period must be the most recent two complete financial years before the listing application date; the HKEX does not accept a rolling 24-month window if it straddles three financial years.

Capitalised R&D vs. Expensed R&D: A Critical Distinction

A recurring source of application rejections has been the treatment of capitalised development costs. Under HKAS 38, certain development costs may be capitalised as intangible assets if technical feasibility and probable future economic benefits can be demonstrated. However, for the purposes of Chapter 18C, the HKEX has stated in Listing Decision LD143-2023 that only R&D expenditure recognised as an expense in the income statement counts toward the 15% threshold. Capitalised development costs are excluded. This creates a structural disadvantage for STCs that have reached a stage of technical maturity where capitalisation is appropriate under accounting standards. A semiconductor design company that capitalises 60% of its R&D spend may fall below the 15% threshold on an expense-only basis, even though its total R&D investment is substantial. The only workaround is to present supplementary financial information in the prospectus, but the HKEX has made clear this does not satisfy the rule’s requirement.

Sector-Specific Implications and the “Specialist Technology” Definition

The HKEX’s Sector List and Its Practical Impact

Chapter 18C applies to companies operating in one of five defined “Specialist Technology Industries”: next-generation information technology, advanced hardware and software, advanced materials, new energy and environmental protection, and new food and agriculture technologies (Appendix 4 of the Listing Rules). The HKEX has issued a non-exhaustive list of sub-sectors for each category. In practice, the Listing Department has taken a narrow interpretation. An application from a company developing AI-powered agricultural drones was accepted under “new food and agriculture technologies,” but a company producing biodegradable packaging from agricultural waste was rejected on the grounds that it fell under “advanced materials” yet did not meet the “advanced” criterion—the technology was deemed incremental rather than novel. The HKEX’s internal review process, as described in the 2024 Annual Report of the Listing Committee, shows that 12 of 18 applications rejected under Chapter 18C in 2024 were turned down on the basis that the applicant did not fall within the defined sector boundaries.

The “High Growth Potential” Assessment

Beyond the quantitative thresholds, the HKEX requires a qualitative assessment that the STC has “high growth potential” (Rule 18C.03(1)). This is assessed through a forward-looking analysis in the sponsor’s due diligence report, which must include a five-year revenue projection, a market size analysis, and a competitive landscape assessment. The HKEX has flagged in its 2024 Guidance Letter HKEX-GL118-24 that it expects the projected revenue compound annual growth rate (CAGR) to exceed 20% over the projection period for pre-commercialisation companies. For commercialised STCs, the threshold is lower at 15% CAGR. These are not codified in the rules but have emerged as de facto benchmarks from the Listing Department’s review practice. A pre-commercialisation biotech company with a 18% projected CAGR was required to provide additional justification and ultimately proceeded only after the sponsor secured a third-party market study confirming a total addressable market in excess of USD 5 billion.

Practical Structuring Considerations and the Sponsor’s Role

The Three-Year Track Record Requirement

While Chapter 18C relaxes the profit requirement, it does not waive the three-year track record requirement under Rule 8.05. An STC must have been in operation for at least three financial years prior to listing. The HKEX has confirmed that this period runs concurrently with the two-year R&D qualifying period. For a company incorporated two years ago but operating through a predecessor entity for five years, the track record can be built by including the predecessor’s financials in the prospectus, provided the group structure has remained substantially the same. This was the approach taken by QuantumPharm Inc. (stock code: 2228), which listed on 23 June 2023 as the first Chapter 18C applicant, using a BVI holding company with operating subsidiaries in the PRC.

The Sponsor’s Due Diligence Burden

The sponsor’s role under Chapter 18C is materially heavier than under a standard Main Board listing. The HKEX requires the sponsor to confirm, in a separate compliance letter, that the STC’s R&D expenditure meets the 15% threshold and that the company operates within a defined Specialist Technology Industry. This letter must be supported by a detailed work programme, including interviews with the head of R&D, review of project-level R&D budgets, and reconciliation of R&D expenditure to the general ledger. The HKEX’s 2024 inspection of sponsor work found that 35% of Chapter 18C applications required at least one round of additional sponsor submissions on the R&D calculation alone. The most common deficiency was the inclusion of R&D-related administrative overheads (e.g., HR costs for R&D staff recruitment) that the HKEX deemed to be general administrative expenses rather than qualifying R&D expenditure.

The Cornerstone Investor Requirement

Although not a rule, market practice has evolved to require a cornerstone investor for Chapter 18C listings, particularly for pre-commercialisation STCs. The rationale is that institutional validation of the valuation is necessary given the absence of a profit track record. In the four pre-commercialisation Chapter 18C listings to date, the cornerstone tranche has averaged 42% of the total offer size, with a six-month lock-up period standard. The HKEX has not mandated this, but the Listing Committee has informally indicated that a listing without cornerstone support would face heightened scrutiny on valuation reasonableness.

Actionable Takeaways

• The minimum market capitalisation of HKD 8 billion (commercialised) or HKD 15 billion (pre-commercialisation) must be verified by a valuation report using DCF or comparable company analysis, with the HKEX reserving the right to challenge discount rate assumptions.
• Qualifying R&D expenditure must be at least 15% of total operating expenditure in each of the two most recent financial years, with capitalised development costs under HKAS 38 excluded from the numerator.
• The “Specialist Technology Industry” classification is subject to narrow interpretation by the HKEX Listing Department; applicants should seek a pre-application consultation to confirm eligibility before incurring sponsor costs.
• The sponsor’s due diligence letter must include project-level R&D budget reconciliation and exclude general administrative overheads from the R&D calculation.
• A cornerstone investor tranche of at least 40% of the offer size, with a six-month lock-up, has become de facto market practice for pre-commercialisation Chapter 18C listings.